CagriSema: Novo Nordisk''s 22.7% Weight Loss Drug Explained
Understand CagriSema, a weekly injection combining cagrilintide and semaglutide, with details on its components and current status.
CagriSema is Novo Nordisk's most ambitious new obesity drug. It combines two separate hormone-targeting mechanisms in a single weekly injection, and Phase 3 data shows it significantly outperforms either component on its own.
The FDA has been reviewing the application since December 2025.
What is CagriSema?
CagriSema is a fixed-dose combination injection containing:
- Cagrilintide 2.4 mg - a long-acting amylin analogue (investigational)
- Semaglutide 2.4 mg - the same GLP-1 agonist in Wegovy (already approved)
It is given as a once-weekly subcutaneous injection, the same format as Wegovy and Mounjaro.
The combination matters because amylin and GLP-1 suppress appetite through different pathways. They work on different brain regions and different receptors. Activating both at the same time produces a stronger and more complementary effect than either hormone alone.
What is amylin, and why does it matter?
Amylin is a hormone produced by the same pancreatic cells that produce insulin. It is released after meals and works alongside insulin to regulate blood sugar and appetite. Its effects include:
- Slowing gastric emptying (food stays in the stomach longer)
- Suppressing glucagon (reduces blood sugar spikes after meals)
- Signalling satiety through the hypothalamus and brainstem
A drug called pramlintide (Symlin) has existed as an amylin analogue for diabetes since 2005, but it required three daily injections and was impractical for most patients. Cagrilintide is a long-acting version designed specifically for once-weekly use.
What do the Phase 3 REDEFINE trials show?
Novo Nordisk ran a comprehensive Phase 3 program under the REDEFINE name.
REDEFINE 1 (Key pivotal trial - obesity without diabetes)
- 3,417 adults with obesity or overweight plus at least one comorbidity
- 68 weeks
- CagriSema: 22.7% average weight loss
- Semaglutide 2.4 mg alone: 16.1%
- Cagrilintide 2.4 mg alone: 11.8%
- Placebo: 2.3%
- This trial was the basis for the NDA submission to the FDA
REDEFINE 2 (Obesity + type 2 diabetes)
- 1,200 adults, 68 weeks
- CagriSema: 15.7% average weight loss vs 3.1% placebo
- 89.7% of patients achieved at least 5% weight loss
REDEFINE 4 (Head-to-head vs Tirzepatide 15 mg)
- 84 weeks, open-label comparison
- CagriSema: 23% weight loss
- Did not achieve non-inferiority versus tirzepatide 15 mg. Tirzepatide performed better.
- This result matters. CagriSema is powerful, but Zepbound remains the current injectable benchmark.
High-dose CagriSema (planned)
Novo Nordisk is also testing a higher-dose formulation (2.4 mg/7.2 mg) with Phase 3 trials planned to start in H2 2026. The higher dose may produce even stronger results.
How does CagriSema compare to other drugs?
| Drug | Mechanism | Status | Avg. weight loss |
|---|---|---|---|
| Wegovy 2.4 mg | GLP-1 | ✅ Approved | ~15–17% |
| Zepbound 15 mg | GIP + GLP-1 | ✅ Approved | ~21% |
| CagriSema 2.4/2.4 mg | Amylin + GLP-1 | FDA review | 22.7–23% |
| Wegovy HD 7.2 mg | GLP-1 | ✅ Approved | ~21% |
CagriSema sits between Zepbound and the emerging pipeline drugs in terms of weight loss efficacy. And it introduces a genuinely novel mechanism, amylin plus GLP-1, not currently available in any approved drug.
What are the side effects?
Side effects in the REDEFINE trials were primarily gastrointestinal, consistent with the semaglutide component:
- Nausea
- Diarrhea
- Vomiting
- Constipation
Most were mild to moderate and diminished over time. CagriSema also showed cardiovascular benefits in the trials, including reduced blood pressure and anti-inflammatory effects.
When will CagriSema be available?
The NDA was submitted to the FDA on December 18, 2025. A standard FDA review takes approximately 10–12 months, which puts a potential approval decision in late 2026.
Final takeaway
CagriSema combines semaglutide with a new amylin analogue to produce significantly stronger weight loss than semaglutide alone. It is in FDA review following a December 2025 submission, with potential approval in late 2026. If approved, it will be the first drug to ever combine GLP-1 and amylin mechanisms, and the first genuinely new obesity drug mechanism in years.
Related Articles
- New GLP-1 Drugs Pipeline 2026–2027: What's Coming
- Retatrutide: The Triple Agonist Explained
- Wegovy HD (High Dose): What You Need to Know
Consult your healthcare provider before making any treatment decisions based on pipeline data.
Sources
- CagriSema FDA history: drugs.com/history/cagrisema.html
- ClinicalTrials.gov: https://clinicaltrials.gov/
- NIDDK — prescription medicines for weight management: https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
- STEP 1 semaglutide trial — PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/
FAQ
What is CagriSema?
CagriSema is a once-weekly injectable combination of cagrilintide (2.4 mg, an amylin analogue) and semaglutide (2.4 mg, a GLP-1 agonist) developed by Novo Nordisk. It is not yet FDA approved - an NDA was submitted in December 2025 and FDA review is expected in 2026.
How much weight does CagriSema cause you to lose?
The REDEFINE 1 Phase 3 trial showed 22.7% average weight loss at 68 weeks in adults with obesity - significantly more than semaglutide alone (16.1%) or cagrilintide alone (11.8%) in the same trial.
What is cagrilintide?
Cagrilintide is a long-acting analogue of amylin, a hormone secreted by the pancreas alongside insulin after eating. Amylin reduces appetite, slows gastric emptying, and suppresses glucagon through different brain pathways to GLP-1. Combining both creates a stronger and more complementary appetite effect.
Is CagriSema better than Wegovy?
In the REDEFINE 1 trial, CagriSema produced 22.7% weight loss vs 16.1% for semaglutide 2.4 mg alone - a meaningful difference. In REDEFINE 4, CagriSema produced 23% weight loss but did not achieve non-inferiority versus tirzepatide 15 mg (Zepbound), which performed better.
When will CagriSema be available?
Novo Nordisk submitted the NDA to the FDA in December 2025. FDA review is expected during 2026. Approval could come in late 2026 if the review proceeds smoothly.
Written by
Masters in Microbiology
Health Content Writer
Anuja Akkar is a Masters in Microbiology professional who contributes evidence-informed health and wellness content for WeightEasy.
View profile →Reviewed by
BHMS
Senior Medical Reviewer
Dietitian with experience in nutrition counseling, meal planning and promoting healthy lifestyles. Dedicated to help individuals achieve optimal health and well-being through personalized nutrition strategies. Skilled in providing expert guidance for managing conditions like diabetes, weight challenges and Lifestyle management.
View profile →